<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/085357</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;085357</article-id><article-id pub-id-type="other" hwp:sub-type="slug">085357</article-id><article-id pub-id-type="other" hwp:sub-type="tag">085357</article-id><article-version>1.1</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Bioinformatics" hwp:journal="biorxiv"><subject>Bioinformatics</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Tissue specificity of <italic toggle="yes">in vitro</italic> drug sensitivity</article-title></title-group><author-notes hwp:id="author-notes-1"><fn id="n1" fn-type="other" hwp:id="fn-1" hwp:rev-id="xref-fn-1-1 xref-fn-1-2 xref-fn-1-3"><label>*</label><p hwp:id="p-1">Co-first authors</p></fn><corresp id="cor2" hwp:id="corresp-1" hwp:rev-id="xref-corresp-1-1"><label>$</label>Corresponding author</corresp><fn fn-type="other" hwp:id="fn-2"><p hwp:id="p-2"><email hwp:id="email-1">f.yao@mail.utoronto.ca</email>
, <email hwp:id="email-2">ali.madanitonekaboni@mail.utoronto.ca</email>, <email hwp:id="email-3">zhaleh.safikhani@utoronto.ca</email>, <email hwp:id="email-4">petr.smirnov@mail.utoronto.ca</email>, <email hwp:id="email-5">nehme.hachem@ircm.qc.ca</email>, <email hwp:id="email-6">mfreem2@uwo.ca</email>, <email hwp:id="email-7">vmanem@uhnresearch.ca</email>, <email hwp:id="email-8">bhaibeka@uhnresearch.ca</email></p></fn></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" hwp:id="contrib-1"><name name-style="western" hwp:sortable="Yao Fupan"><surname>Yao</surname><given-names>Fupan</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="author-notes" rid="n1" hwp:id="xref-fn-1-1" hwp:rel-id="fn-1">*</xref></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Tonekaboni Seyed Ali Madani"><surname>Tonekaboni</surname><given-names>Seyed Ali Madani</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref><xref ref-type="author-notes" rid="n1" hwp:id="xref-fn-1-2" hwp:rel-id="fn-1">*</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Safikhani Zhaleh"><surname>Safikhani</surname><given-names>Zhaleh</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-2" hwp:rel-id="aff-2">2</xref><xref ref-type="author-notes" rid="n1" hwp:id="xref-fn-1-3" hwp:rel-id="fn-1">*</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Smirnov Petr"><surname>Smirnov</surname><given-names>Petr</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-4" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-3" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="El-Hachem Nehme"><surname>El-Hachem</surname><given-names>Nehme</given-names></name><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-1" hwp:rel-id="aff-3">3</xref><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-1" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Freeman Mark"><surname>Freeman</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-5" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-7"><name name-style="western" hwp:sortable="Manem Venkata Satya Kumar"><surname>Manem</surname><given-names>Venkata Satya Kumar</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-6" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-4" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-8"><name name-style="western" hwp:sortable="Haibe-Kains Benjamin"><surname>Haibe-Kains</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-7" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-5" hwp:rel-id="aff-2">2</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-1" hwp:rel-id="aff-5">5</xref><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-1" hwp:rel-id="aff-6">6</xref><xref ref-type="corresp" rid="cor2" hwp:id="xref-corresp-1-1" hwp:rel-id="corresp-1">$</xref></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3 xref-aff-1-4 xref-aff-1-5 xref-aff-1-6 xref-aff-1-7"><label>1</label><institution hwp:id="institution-1">Princess Margaret Cancer Centre</institution>, Toronto, Ontario M5G 1L7, <country>Canada</country></aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1 xref-aff-2-2 xref-aff-2-3 xref-aff-2-4 xref-aff-2-5"><label>2</label><institution hwp:id="institution-2">Department of Medical Biophysics, University of Toronto</institution>, Toronto, Ontario M5G 1L7, <country>Canada</country></aff><aff id="a3" hwp:id="aff-3" hwp:rev-id="xref-aff-3-1"><label>3</label><institution hwp:id="institution-3">Integrative systems biology, Institut de Recherches Cliniques de Montréal</institution>, Montreal, Quebec, <country>Canada</country></aff><aff id="a4" hwp:id="aff-4" hwp:rev-id="xref-aff-4-1"><label>4</label><institution hwp:id="institution-4">Department of Medicine, University of Montreal</institution>, Montréal, Quebec, <country>Canada</country></aff><aff id="a5" hwp:id="aff-5" hwp:rev-id="xref-aff-5-1"><label>5</label><institution hwp:id="institution-5">Department of Computer Science, University of Toronto</institution>, Toronto, Ontario M5T 3A1, <country>Canada</country></aff><aff id="a6" hwp:id="aff-6" hwp:rev-id="xref-aff-6-1"><label>6</label><institution hwp:id="institution-6">Ontario Institute of Cancer Research</institution>, Toronto, Ontario M5G 1L7, <country>Canada</country></aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2016"><year>2016</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2016-11-03T06:33:44-07:00">
    <day>3</day><month>11</month><year>2016</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2016-11-03T06:33:44-07:00">
    <day>3</day><month>11</month><year>2016</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2016-11-03T06:50:54-07:00">
    <day>3</day><month>11</month><year>2016</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2016-11-03T06:50:54-07:00">
    <day>3</day><month>11</month><year>2016</year>
  </pub-date><elocation-id>085357</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2016-11-02"><day>02</day><month>11</month><year>2016</year></date>
<date date-type="accepted" hwp:start="2016-11-03"><day>03</day><month>11</month><year>2016</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2016, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2016</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" hwp:id="license-1"><p hwp:id="p-3">This pre-print is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), CC BY-NC 4.0, as described at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://creativecommons.org/licenses/by-nc/4.0/" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" hwp:id="ext-link-1">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></p></license></permissions><self-uri xlink:href="085357.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/085357v1.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="085357.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/085357v1/085357v1.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/085357v1/085357v1.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">ABSTRACT</title><p hwp:id="p-4">Research in oncology traditionally focuses on specific tissue type from which the cancer develops. However, advances in high-throughput molecular profiling technologies have enabled the comprehensive characterization of molecular aberrations in multiple cancer types. It was hoped that these large-scale datasets would provide the foundation for a paradigm shift in oncology which would see tumors being classified by their molecular profiles rather than tissue types, but tumors with similar genomic aberrations may respond differently to targeted therapies depending on their tissue of origin. There is therefore a need to reassess the potential association between pharmacological response and tissue of origin for therapeutic drugs, and to test how these associations translate from preclinical to clinical settings.</p><p hwp:id="p-5">In this paper, we investigate the tissue specificity of drug sensitivities in large-scale pharmacological studies and compare these associations to those found in clinical trial descriptions. Our meta-analysis of the four largest <italic toggle="yes">in vitro</italic> drug screening datasets indicates that tissue of origin is strongly associated with drug response. We identify novel tissue-drug associations, which may present exciting new avenues for drug repurposing. One caveat is that the vast majority of the significant associations found in preclinical settings do not concur with clinical observations. Accordingly, our results call for more testing to find the root cause of the discrepancies between preclinical and clinical observations.</p></abstract><counts><page-count count="32"/></counts></article-meta></front><body><sec id="s1" hwp:id="sec-1"><title hwp:id="title-2">INTRODUCTION</title><p hwp:id="p-6">Large projects, such as The Cancer Genome Atlas [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>] and the International Cancer Genome Consortium [<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref>], have enabled the comprehensive characterization of molecular aberrations in multiple cancer types. The collection of mutations, copy number variations, gene expressions and other features enabled molecularly-based patient stratification across diverse tumor types, potentially creating a shift from the traditional classification based on tissue type [<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref>–<xref ref-type="bibr" rid="c5" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">5</xref>]. However, tumors with similar genomic aberrations may respond differently to cytotoxic and targeted therapies, suggesting that tissue-of-origin is unlikely to be supplanted by molecular stratifications [<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref>].</p><p hwp:id="p-7">Testing drug potency in large populations of patients suffering different cancer types is an expensive and lengthy process [<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref>]. Cancer cell lines provide a safe and cost-efficient methodology to measure drug response in multiple cancer types [<xref ref-type="bibr" rid="c8" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref>]. However, the translation of these preclinical findings in animal studies [<xref ref-type="bibr" rid="c9" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">9</xref>, <xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref>] and in clinical settings [<xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref>] is complex, as cancer cell lines substantially differ from the patient tumors they originate from [<xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref>, <xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">13</xref>]. This discrepancy has several causes. Repeatedly culturing cell lines allows for the potential acquisition of genomic aberrations, causing the cell lines to diverge from their initial samples [<xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref>]. In addition, mislabeling, simple clerical mistakes in cell line annotations, and cross-contamination can also cause additional skewing of drug screening results [<xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref>–<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref>]. Despite these drawbacks, cell lines are the only model systems currently enabling high-throughput drug screening and will therefore remain models of choice for drug development and biomarker discovery [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">18</xref>–<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref>].</p><p hwp:id="p-8">In a recent paper investigating a pharmacogenomic dataset of 59 cell lines (NCI60), Jaeger et al. observed that drugs designed for specific tissue types, such as lapatinib for breast cancer, had similar activity across all tested tissue types, rather than a unique sensitivity pattern for the targeted tissue type [<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref>]. Despite the small number of cell lines in NCI60, the authors concluded that cancer-specific drugs do not show higher efficacies in cell lines representing the tissue of interest, raising doubts about the relevance of <italic toggle="yes">in vitro</italic> screening for drug discovery and repurposing. If the results of this seminal study generalize to larger panel of cell lines, this would call for more curation of established cell lines to verify their tissues of origin, and for the generation of new cell lines or organoids freshly derived from patients as better models for high-throughput drug screening [<xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-2" hwp:rel-id="ref-10">10</xref>, <xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">25</xref>, <xref ref-type="bibr" rid="c26" hwp:id="xref-ref-26-1" hwp:rel-id="ref-26">26</xref>].</p><p hwp:id="p-9">The recent release of multiple large-scale pharmacogenomic datasets enables analysis of sensitivities of thousands of cell lines to hundreds of drugs [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-2" hwp:rel-id="ref-18">18</xref>–<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref>, <xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-2" hwp:rel-id="ref-23">23</xref>]. Subsequent evaluation of these datasets, however, found only moderate inter-laboratory concordance in the drug response phenotypes [<xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref>, <xref ref-type="bibr" rid="c27" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">27</xref>–<xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-1" hwp:rel-id="ref-30">30</xref>], highlighting the need for meta-analysis of these valuable, yet complex studies [<xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">31</xref>]. Such meta-analysis is hindered by the lack of standardization in cell line and drug identifiers. We addressed this issue by developing the <italic toggle="yes">PharmacoGx</italic> platform, which provides a computational system to allow for unified processing of pharmacogenomic datasets curated with standard cell line and drug identifiers [<xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-1" hwp:rel-id="ref-32">32</xref>].</p><p hwp:id="p-10">In this work, we leveraged <italic toggle="yes">PharmacoGx</italic> to robustly assess the specificity of 727 experimental and approved drugs to 1527 unique cancer cell lines originating from 35 different tissue types. We then compared the significant drug-tissue associations identified <italic toggle="yes">in vitro</italic> to clinical observations. Our meta-analysis results indicate that tissue of origin is strongly predictive of drug response <italic toggle="yes">in vitro.</italic> However we found that, except for a few drugs, the vast majority of these preclinical associations did not concur with results from clinical trials, calling for further investigations of the relevance of cancer cell lines for drug sensitivities in specific tissue types.</p></sec><sec id="s2" hwp:id="sec-2"><title hwp:id="title-3">METHODS</title><p hwp:id="p-11">The overall analysis design is represented in <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1</xref>.</p><fig id="fig1" position="float" orientation="portrait" fig-type="figure" hwp:id="F1" hwp:rev-id="xref-fig-1-1 xref-fig-1-2 xref-fig-1-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1:</label><caption hwp:id="caption-1"><title hwp:id="title-4">Schematic representation of data input and analysis pipeline.</title></caption><graphic xlink:href="085357_fig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig><sec id="s2a" hwp:id="sec-3"><title hwp:id="title-5">Pharmacogenomic datasets</title><p hwp:id="p-12">We curated the four largest pharmacogenomic datasets within our <italic toggle="yes">PharmacoGx</italic> platform [<xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-2" hwp:rel-id="ref-32">32</xref>]: The Cancer Cell Line Encyclopedia (CCLE) [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-3" hwp:rel-id="ref-18">18</xref>], the Genomics of Drug Sensitivity in Cancer (GDSC1000) [<xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">19</xref>, <xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-3" hwp:rel-id="ref-23">23</xref>, <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-1" hwp:rel-id="ref-33">33</xref>], the Cancer Therapy Response Portal (CTRPv2) [<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-2" hwp:rel-id="ref-21">21</xref>, <xref ref-type="bibr" rid="c34" hwp:id="xref-ref-34-1" hwp:rel-id="ref-34">34</xref>], and the Genentech Cell Line Screening Initiative (gCSl) [<xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-2" hwp:rel-id="ref-20">20</xref>] (<xref ref-type="table" rid="tbl1" hwp:id="xref-table-wrap-1-1" hwp:rel-id="T1">Table 1</xref>). Cell lines were annotated using the Cellosaurus annotation database [<xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-1" hwp:rel-id="ref-35">35</xref>], while drugs were annotated using SMILES structures [<xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-1" hwp:rel-id="ref-36">36</xref>], PubChem ID [<xref ref-type="bibr" rid="c37" hwp:id="xref-ref-37-1" hwp:rel-id="ref-37">37</xref>], and InChiKeys [<xref ref-type="bibr" rid="c38" hwp:id="xref-ref-38-1" hwp:rel-id="ref-38">38</xref>]. All curated data were stored as <italic toggle="yes">PharmacoSet</italic> objects with our <italic toggle="yes">PharmacoGx</italic> platform (version 1.3.4) [<xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-3" hwp:rel-id="ref-32">32</xref>].</p><table-wrap id="tbl1" orientation="portrait" position="float" hwp:id="T1" hwp:rev-id="xref-table-wrap-1-1 xref-table-wrap-1-2 xref-table-wrap-1-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>Table 1:</label><caption hwp:id="caption-2"><p hwp:id="p-13"><bold>Characteristics of the pharmacogenomic datasets.</bold></p></caption><graphic xlink:href="085357_tbl1" position="float" orientation="portrait" hwp:id="graphic-2"/></table-wrap></sec><sec id="s2b" hwp:id="sec-4"><title hwp:id="title-6">Tissue of origin of cancer cell lines</title><p hwp:id="p-14">We used the Catalog of Somatic Mutations in Cancer (COSMIC) nomenclature to consistently annotate cancer cell lines with their tissue of origin [<xref ref-type="bibr" rid="c39" hwp:id="xref-ref-39-1" hwp:rel-id="ref-39">39</xref>]. Tissues with less than 5 cancer cell lines were removed in each dataset to ensure sufficient sample number for subsequent analyses.</p></sec><sec id="s2c" hwp:id="sec-5"><title hwp:id="title-7">Drug sensitivity</title><p hwp:id="p-15">To ensure consistent evaluation of drug sensitivity, we used our <italic toggle="yes">PharmacoGx</italic> platform to reprocess the drug dose-response curves in our compendium of pharmacogenomic datasets [<xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-4" hwp:rel-id="ref-32">32</xref>]. All dose-response curves were fitted to the equation <inline-formula hwp:id="inline-formula-1"><alternatives hwp:id="alternatives-1"><inline-graphic xlink:href="085357_inline1.gif" hwp:id="inline-graphic-1"/></alternatives></inline-formula>, where <italic toggle="yes">y</italic> = 0 denotes death of all cancer cells within a sample, <italic toggle="yes">y</italic> = <italic toggle="yes">y</italic>(0) = 1 denotes no effect of the drug dose on the cancer cell sample, <italic toggle="yes">EC</italic><sub>50</sub> is the concentration at which viability is reduced to half of the viability observed in the presence of an arbitrarily large concentration of drug, and Hill Slope (<italic toggle="yes">HS</italic>) is a parameter describing the cooperativity of binding. <italic toggle="yes">HS</italic> &lt; 1 denotes negative binding cooperativity, <italic toggle="yes">HS</italic> = 1 denotes noncooperative binding, and <italic toggle="yes">HS</italic> &gt; 1 denotes positive binding cooperativity. The parameters of the curves were fitted using the least squares optimization framework. We used the area above the dose-response curves (AUC ∈ [0, 1]) to quantify drug sensitivity across cell lines, as AUC is always defined (as opposed to IC<sub>50</sub>) and combines potency and efficacy of a drug into a single parameter [<xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-1" hwp:rel-id="ref-40">40</xref>]. In this work, high AUC is indicative of sensitivity to a given drug.</p></sec><sec id="s2d" hwp:id="sec-6"><title hwp:id="title-8">Tissue specificity of drug sensitivity</title><p hwp:id="p-16"><italic toggle="yes">Identification of drug-tissue associations using enrichment analysis.</italic> For each drug, cell lines were first ranked based on their drug sensitivity (AUC) in each dataset separately. We then adapted the gene set enrichment analysis [<xref ref-type="bibr" rid="c41" hwp:id="xref-ref-41-1" hwp:rel-id="ref-41">41</xref>] implemented in the <italic toggle="yes">piano</italic> package [<xref ref-type="bibr" rid="c42" hwp:id="xref-ref-42-1" hwp:rel-id="ref-42">42</xref>] to test whether this ranked list is enriched in sensitive cell lines belonging to a specific tissue type (Supplementary <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-2" hwp:rel-id="F1">Figure 1</xref>). Our tissue enrichment analysis (TEA) therefore allowed us to compute the significance of the association between each tissue and drug sensitivity using 10,000 cell line permutations in the tissue set. TEA was performed for each drug separately.</p><p hwp:id="p-17"><italic toggle="yes">Meta-analysis of drug-tissue associations</italic>: Applying TEA to each dataset generates a set of p-values for each drug-tissue association. These p-values were combined using the weighted Z method [<xref ref-type="bibr" rid="c43" hwp:id="xref-ref-43-1" hwp:rel-id="ref-43">43</xref>] implemented in the <italic toggle="yes">combine.test</italic> function of our <italic toggle="yes">survcomp</italic> package [<xref ref-type="bibr" rid="c44" hwp:id="xref-ref-44-1" hwp:rel-id="ref-44">44</xref>]. Weights were defined as the number of cell lines in a given tissue type in each dataset from which the p-value has been computed. These combined p-values were subsequently adjusted using the false discovery rate (FDR) procedure [<xref ref-type="bibr" rid="c45" hwp:id="xref-ref-45-1" hwp:rel-id="ref-45">45</xref>] for all drugs.</p></sec><sec id="s2e" hwp:id="sec-7"><title hwp:id="title-9">Clinical drug-tissue associations</title><p hwp:id="p-18">To extract known drug-tissue association from the literature, we downloaded the list of clinical trials and associated metadata from ClinicalTrials.gov (last updated October 10th, 2016) and parsed these data using the XML R package (version 3.98-1.4). We then mined these clinical data to identify drug and tissue names. The co-occurrence of a drug with a tissue type was considered to constitute a drug-tissue association supported by clinical evidence. We also complemented our set of clinical drug-tissue associations by including the curation done by Jaeger et al. (Additional Files 1 and 2 in [<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-2" hwp:rel-id="ref-24">24</xref>]).</p></sec><sec id="s2f" hwp:id="sec-8"><title hwp:id="title-10">Comparison of drug-tissue associations between preclinical and clinical settings</title><p hwp:id="p-19">To test whether drug-tissue associations observed in clinical trials were recapitulated <italic toggle="yes">in vitro,</italic> we compared the sets of preclinical and clinical associations by restricting our analysis to the associations tested in our meta-analysis of the pharmacogenomic data. We used Cytoscape version 3.3.0 [<xref ref-type="bibr" rid="c46" hwp:id="xref-ref-46-1" hwp:rel-id="ref-46">46</xref>] to visualize the associations observed in preclinical, clinical settings, or both as a network with colored edges in a Circos plot [<xref ref-type="bibr" rid="c47" hwp:id="xref-ref-47-1" hwp:rel-id="ref-47">47</xref>]. The Matthew correlation coefficient (MCC) [<xref ref-type="bibr" rid="c48" hwp:id="xref-ref-48-1" hwp:rel-id="ref-48">48</xref>] was used to quantify the strength of association between preclinical and clinical drug-tissue associations, and the significance was computed using a permutation test as implemented in the <italic toggle="yes">PharmacoGx</italic> R package (version 1.3.4) [<xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-5" hwp:rel-id="ref-32">32</xref>].</p></sec><sec id="s2g" hwp:id="sec-9"><title hwp:id="title-11">Research replicability</title><p hwp:id="p-20">This study complies with the standards of research reproducibility published by Sandve et al. [<xref ref-type="bibr" rid="c49" hwp:id="xref-ref-49-1" hwp:rel-id="ref-49">49</xref>]. The datasets are freely available through our <italic toggle="yes">PharmacoGx</italic> platform [<xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-6" hwp:rel-id="ref-32">32</xref>]. The code to replicate the analysis results, figures and tables is open-access and available on GitHub (<ext-link l:rel="related" l:ref-type="uri" l:ref="http://github.com/bhklab/DrugTissue" ext-link-type="uri" xlink:href="http://github.com/bhklab/DrugTissue" hwp:id="ext-link-2">github.com/bhklab/DrugTissue</ext-link>). In addition, we have set up a Docker virtual environment [<xref ref-type="bibr" rid="c50" hwp:id="xref-ref-50-1" hwp:rel-id="ref-50">50</xref>] is available online with all required R packages and tools pre-installed to facilitate replication of the study results. A detailed description of the software environment and the main steps to replicate the figures and tables is provided in Supplementary Information.</p></sec></sec><sec id="s3" hwp:id="sec-10"><title hwp:id="title-12">RESULTS</title><p hwp:id="p-21">Given the increasingly prominent use of high-throughput <italic toggle="yes">in vitro</italic> testing in biomedical research, we sought to test whether cancer cell lines originating from specific tissues responded differently to a large set of cytotoxic and targeted therapies. We therefore analyzed the four largest pharmacogenomic datasets published to date, namely CCLE, GDSC1000, CTRPv2 and gCSI (<xref ref-type="table" rid="tbl1" hwp:id="xref-table-wrap-1-2" hwp:rel-id="T1">Table 1</xref>). These datasets contain 24 tissue types represented by at least 5 cell lines across all datasets (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figure 2A</xref>). Importantly, our curation [<xref ref-type="bibr" rid="c27" hwp:id="xref-ref-27-2" hwp:rel-id="ref-27">27</xref>, <xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-2" hwp:rel-id="ref-30">30</xref>, <xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-7" hwp:rel-id="ref-32">32</xref>] revealed that these studies investigated many identical cell lines and drugs, including 303 cell lines and 4 drugs—erlotinib, lapatinib, paclitaxel and crizotinib—screened in all four datasets (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Figure 2B</xref>; Supplementary File 1).</p><fig id="fig2" position="float" orientation="portrait" fig-type="figure" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2:</label><caption hwp:id="caption-3"><title hwp:id="title-13">Composition and overlap of our compendium of pharmacogenomic datasets.</title><p hwp:id="p-22">(<bold>A</bold>) Number of cell lines representing each tissue type with respect to their source dataset. Tissue types represented by less than 5 cell lines in a given dataset were removed for the dataset. (<bold>B</bold>) Overlap for drugs, cell lines and tissue types across datasets.</p></caption><graphic xlink:href="085357_fig2" position="float" orientation="portrait" hwp:id="graphic-3"/></fig><p hwp:id="p-23">We leveraged our compendium of pharmacogenomic datasets to identify statistically significant drug-tissue associations <italic toggle="yes">in vitro</italic> using our Tissue Enrichment Analysis (TEA; Supplementary <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-3" hwp:rel-id="F1">Figure 1</xref>). We reported the enrichment scores and associated p-values for the 16 drugs screened in at least 3 datasets in Supplementary File 2. Out of 722 drugs in our data compendium, we found that 631 (87%) of drugs yielded significantly higher sensitivities in at least one tissue type (FDR&lt;5%; Supplementary File 3). Interestingly, 17-AAG, trametinib, afatinib, docetaxel yielded significantly enriched sensitivities in more than 5 tissue types (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figure 3A-D</xref>), while less than 10% of the drugs, such as betulinic acid and MS275, showed no dependency of sensitivity to tissues (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Figure 3E,F</xref>).</p><fig id="fig3" position="float" orientation="portrait" fig-type="figure" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Figure 3:</label><caption hwp:id="caption-4"><title hwp:id="title-14">Distribution of drug sensitivities with respect to tissue types for drugs yielding the strongest(A-D) and weakest (E-F) tissue associations.</title><p hwp:id="p-24">Tissue enriched in drug sensitivities are highlighted in red.</p></caption><graphic xlink:href="085357_fig3" position="float" orientation="portrait" hwp:id="graphic-4"/></fig><p hwp:id="p-25">Despite the large number of drugs with enriched sensitivity in at least one tissue type, only 6% of all the drug-tissue associations assessed in our study (1,025/17,371) were significant (FDR&lt;5%). We investigated whether these significant associations were uniformly distributed across tissues types. There was no significant correlation between the number of drug-tissue associations and the number of cell lines in each tissue type (Spearman correlation coefficient ρ=0.05, p-value=0.80, which was expected because TEA controls for the size of tissue sets during the permutation testing procedure. We found that the pleura tissue and breast luminal B subtype of breast cancer have no drug-tissue associations (<xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-1" hwp:rel-id="F4">Figure 4A</xref>). Concurring with previous reports [<xref ref-type="bibr" rid="c51" hwp:id="xref-ref-51-1" hwp:rel-id="ref-51">51</xref>, <xref ref-type="bibr" rid="c52" hwp:id="xref-ref-52-1" hwp:rel-id="ref-52">52</xref>], the “hematopoietic and lymphoid” tissue was significantly enriched in sensitive cell lines for more than 500 drugs (65%; <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-2" hwp:rel-id="F4">Figure 4A</xref>), suggesting that these cell lines are highly sensitive to chemical perturbations. To examine the impact of this tissue on the overall analysis, TEA was rerun removing all the corresponding cell lines (217 unique cell lines). The number of significant drug-tissue associations proportionally decreased (6% v.s. 3% for the full analysis and without hematopoietic and lymphoid tissue, respectively), suggesting that the associations with other tissues are not drastically influenced by the presence of the hematopoietic and lymphoid tissue.</p><fig id="fig4" position="float" orientation="portrait" fig-type="figure" hwp:id="F4" hwp:rev-id="xref-fig-4-1 xref-fig-4-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>Figure 4:</label><caption hwp:id="caption-5"><title hwp:id="title-15">Distribution of <italic toggle="yes">in vitro</italic> drug-tissue associations.</title><p hwp:id="p-26">(<bold>A</bold>) Number of significantly associated drugs for each tissue type in our compendium; (<bold>B</bold>) Number of significantly associated tissues for drugs with 3 or more associations.</p></caption><graphic xlink:href="085357_fig4" position="float" orientation="portrait" hwp:id="graphic-5"/></fig><p hwp:id="p-27">Although our meta-analysis leverages the four largest pharmacogenomic studies published to date, these datasets vary in terms of the number of drug dose-response curves actually measured (<xref ref-type="table" rid="tbl1" hwp:id="xref-table-wrap-1-3" hwp:rel-id="T1">Table 1</xref>). We therefore assessed which dataset contributed the most to the discovery of statistically significant <italic toggle="yes">in vitro</italic> drug-tissue associations. As expected, the two largest datasets, namely GDSC1000 and CTRPv2, contributed several times more associations than gCSI and CCLE (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-1" hwp:rel-id="F5">Figure 5</xref>). Interestingly, more than half of significant drug-tissue associations are “private”, i.e., they were found in one dataset but were not consistent across datasets. On the contrary, a substantial proportion of associations were not significant in each individual datasets but were selected during the meta-analysis phase based on their consistent trend to significance (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-2" hwp:rel-id="F5">Figure 5</xref>). These results support the benefit of combining multiple pharmacogenomic datasets in a meta-analysis framework.</p><fig id="fig5" position="float" orientation="portrait" fig-type="figure" hwp:id="F5" hwp:rev-id="xref-fig-5-1 xref-fig-5-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/FIG5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F5</object-id><object-id pub-id-type="publisher-id">fig5</object-id><label>Figure 5:</label><caption hwp:id="caption-6"><title hwp:id="title-16">Number of drug-tissue associations in each pharmacogenomic dataset and meta-analysis.</title><p hwp:id="p-28">The associations that are significant in a dataset and also in the meta-analysis are colored in blue. The associations found significant in a dataset but not selected after meta-analysis are colored in red. The associations found non-significant in a dataset but ended up selected after meta-analysis are colored in green.</p></caption><graphic xlink:href="085357_fig5" position="float" orientation="portrait" hwp:id="graphic-6"/></fig><p hwp:id="p-29">We further investigated the impact of sample size, that is the number of cell lines screened for drug sensitivity, on the TEA. When restricting our analysis to the NCI60 cell line panel (59 cell lines from 9 tissue types) and the 86 drugs in common with our compendium, we found less significant drug-tissue associations (16 v.s. 80 for NCI60 and our compendium, respectively; Supplementary <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Figure 2</xref>), indicating that the number cell lines in NCI60 is not sufficient to identify most of the drug-tissue associations. Analyzing the full set of 50,978 drugs in NCI60, we also found a substantially lower proportion of drug-tissue associations to be significant for the drugs and 9 tissue types present in our NCI60 PSet (6% v.s. 0.22% with FDR&lt;5% for our compendium and NCI60, respectively; Supplementary <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Figure 3</xref>; Supplementary Files 3 and 4).</p><p hwp:id="p-30">Given the significant tissue specificity of most drugs <italic toggle="yes">in vitro</italic>, we sought to assess whether these associations were consistent with clinical observations regarding the efficacy of drugs in specific tissue types. We therefore mined a large set of clinical trials to extract co-occurrences of tissues and drugs in the trial descriptions published in <ext-link l:rel="related" l:ref-type="uri" l:ref="http://ClinicalTrials.gov" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" hwp:id="ext-link-3">ClinicalTrials.gov</ext-link>. Distribution of co-occurrences for each drug with tissue types is shown in <xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-1" hwp:rel-id="F6">Figure 6A</xref>. We found 535 potential drug-tissue associations tested in clinical settings. Despite the large number of <italic toggle="yes">in vitro</italic> and clinical associations, the overlap was small (MCC=-0.004, p=0.99; <xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-2" hwp:rel-id="F6">Figure 6B</xref>). We confirmed the lack of global concordance between preclinical and clinical drug-tissue associations using the manual curation of Jaeger et al. (<xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-3" hwp:rel-id="F6">Figure 6C</xref>). Interestingly, we observed that afatinib and lapatinib, two of the drugs with the most number of tissue associations <italic toggle="yes">in vitro</italic>, are part of the small set of conserved drug-tissue associations (<xref ref-type="table" rid="tbl2" hwp:id="xref-table-wrap-2-1" hwp:rel-id="T2">Table 2</xref>; <xref ref-type="fig" rid="fig7" hwp:id="xref-fig-7-1" hwp:rel-id="F7">Figure 7</xref>), suggesting that the strongest <italic toggle="yes">in vitro</italic> associations can be translated into clinical setting. However, we consider such a finding to be weak at best as this represents a very small set of associations.</p><fig id="fig6" position="float" orientation="portrait" fig-type="figure" hwp:id="F6" hwp:rev-id="xref-fig-6-1 xref-fig-6-2 xref-fig-6-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/FIG6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F6</object-id><object-id pub-id-type="publisher-id">fig6</object-id><label>Figure 6:</label><caption hwp:id="caption-7"><title hwp:id="title-17">Comparison of preclinical and clinical drug-tissue associations.</title><p hwp:id="p-31">(<bold>A</bold>) Distribution of (drug, tissue) co-occurrences from records in ClinicalTrials.gov. <bold>(B</bold>) Contingency table for the drug-tissue association <italic toggle="yes">in vitro</italic> and drug-tissue co-occurrence in clinical trials. (<bold>C</bold>) overlap of interactions found <italic toggle="yes">in vitro</italic> and in clinical data from Jaeger et al and clinical trials. (<bold>D</bold>) interaction graph showing clinical trial data against preclinical data: Red lines represent drug-tissue associations observed only <italic toggle="yes">in vitro</italic> (referred to as experimental). Pink lines indicate experimental relationships with no clinical application. Green lines indicate a clinical application not recognized in preclinical analysis. Blue lines indicate <italic toggle="yes">in vitro</italic> drug-tissue associations supported by clinical applications.</p></caption><graphic xlink:href="085357_fig6" position="float" orientation="portrait" hwp:id="graphic-7"/></fig><table-wrap id="tbl2" orientation="portrait" position="float" hwp:id="T2" hwp:rev-id="xref-table-wrap-2-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/TBL2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T2</object-id><object-id pub-id-type="publisher-id">tbl2</object-id><label>Table 2:</label><caption hwp:id="caption-8"><p hwp:id="p-32"><bold>List of drug-tissue associations conserved across <italic toggle="yes">in vitro</italic> and clinical settings.</bold></p></caption><graphic xlink:href="085357_tbl2" position="float" orientation="portrait" hwp:id="graphic-8"/></table-wrap><fig id="fig7" position="float" orientation="portrait" fig-type="figure" hwp:id="F7" hwp:rev-id="xref-fig-7-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/FIG7</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F7</object-id><object-id pub-id-type="publisher-id">fig7</object-id><label>Figure 7:</label><caption hwp:id="caption-9"><title hwp:id="title-18">Circos plot representing the significant associations for drugs with clinical trial evidence.</title><p hwp:id="p-33">Blue and yellow boxes represent the drugs and tissues, respectively. Red lines represent drug-tissue associations observed only <italic toggle="yes">in vitro</italic> (referred to as experimental). Pink lines indicate experimental relationships with no clinical application. Green lines indicate a clinical application not recognized in preclinical analysis. Blue lines indicate <italic toggle="yes">in vitro</italic> drug-tissue associations supported by clinical applications.</p></caption><graphic xlink:href="085357_fig7" position="float" orientation="portrait" hwp:id="graphic-9"/></fig></sec><sec id="s4" hwp:id="sec-11"><title hwp:id="title-19">DISCUSSION</title><p hwp:id="p-34">One of the main challenges in precision cancer medicine is to select drugs likely to yield response for each patient. Most of the current treatment regimens for cancer are based on the tissue of origin, as therapies are being designed for specific tissues [<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-2" hwp:rel-id="ref-6">6</xref>, <xref ref-type="bibr" rid="c53" hwp:id="xref-ref-53-1" hwp:rel-id="ref-53">53</xref>]. Recent high-throughput <italic toggle="yes">in vitro</italic> drug screening studies investigating large panels of cancer cell lines from multiple tissues [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-4" hwp:rel-id="ref-18">18</xref>–<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-3" hwp:rel-id="ref-21">21</xref>, <xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-4" hwp:rel-id="ref-23">23</xref>] provide us with a unique opportunity to assess the association between drug sensitivity and tissue types [<xref ref-type="bibr" rid="c53" hwp:id="xref-ref-53-2" hwp:rel-id="ref-53">53</xref>]. However, it remains unclear to which extent cancer cell lines originating from different tissue types respond differently to a variety of cytotoxic and targeted drugs [<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-3" hwp:rel-id="ref-24">24</xref>, <xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-1" hwp:rel-id="ref-28">28</xref>, <xref ref-type="bibr" rid="c51" hwp:id="xref-ref-51-2" hwp:rel-id="ref-51">51</xref>, <xref ref-type="bibr" rid="c52" hwp:id="xref-ref-52-2" hwp:rel-id="ref-52">52</xref>, <xref ref-type="bibr" rid="c54" hwp:id="xref-ref-54-1" hwp:rel-id="ref-54">54</xref>, <xref ref-type="bibr" rid="c55" hwp:id="xref-ref-55-1" hwp:rel-id="ref-55">55</xref>]. If these drug-tissue associations recapitulated the differential drug response across tissues observed in clinic, this would open a new avenue of research for tissue-based drug repurposing. In this study, we addressed these two issues in the largest meta-analysis of pan-cancer <italic toggle="yes">in vitro</italic> drug screening data published to date.</p><p hwp:id="p-35">Our large compendium of drugs and cancer cell lines representing 25 tissue types, combined with our tissue enrichment analysis, allowed us to identify a large number of <italic toggle="yes">in vitro</italic> drug-tissue associations. Our results indicate that the vast majority of the drugs (87%) yield higher sensitivity in at least one tissue type. Our meta-analysis shed new light on the recent controversy regarding the tissue specificity of drug sensitivity screens, where studies reported substantial tissue-specific drug response [<xref ref-type="bibr" rid="c51" hwp:id="xref-ref-51-3" hwp:rel-id="ref-51">51</xref>, <xref ref-type="bibr" rid="c52" hwp:id="xref-ref-52-3" hwp:rel-id="ref-52">52</xref>], and the contrary [<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-4" hwp:rel-id="ref-24">24</xref>]. This controversy is partly due to the lack of consensus definition of tissue specificity. In our study and the previous work from Klijn et al. [<xref ref-type="bibr" rid="c51" hwp:id="xref-ref-51-4" hwp:rel-id="ref-51">51</xref>] and Gupta et al [<xref ref-type="bibr" rid="c52" hwp:id="xref-ref-52-4" hwp:rel-id="ref-52">52</xref>], tissue specificity is defined as an association between drug sensitivity and <italic toggle="yes">any</italic> tissue type, while Jaeger et al. [<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-5" hwp:rel-id="ref-24">24</xref>] only considered associations with the tissues the drugs have been developed for. The latter set of associations is therefore a subset of all drug-tissue associations that can be identified <italic toggle="yes">in vitro</italic>. However, using the broader definition of tissue specificity, our results indicate that the small panel of 59 cell lines screened in the NCI60 dataset and used in Jaeger et al. [<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-6" hwp:rel-id="ref-24">24</xref>] is not sufficient to identify most of the <italic toggle="yes">in vitro</italic> drug-tissue associations. Moreover, we also demonstrated that the meta-analysis framework used in this study, allowed us not only to identify more drug-tissue associations, but also to discard the drug-tissue associations that were not consistent across multiple datasets, increasing the robustness of our results.</p><p hwp:id="p-36">While tissue-specificity of drug sensitivity <italic toggle="yes">in vitro</italic> is relevant for drug development in the preclinical setting, its translational potential in clinical setting remains unclear. In this regard, the study from Jaeger et al. was seminal as the authors compared <italic toggle="yes">in vitro</italic> drug response patterns to clinical observations in breast, colorectal and prostate cancers and found no concordance [<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-7" hwp:rel-id="ref-24">24</xref>]. Given that our results indicate strong tissue specificity of <italic toggle="yes">in vitro</italic> drug sensitivity, we tested the concordance of preclinical and clinical observations in more than 23 tissue types. Although we found that the drugs showing the strongest tissue-specificity (afatinib and lapatinib) were more likely to be tested in clinical trials with their associated tissue types than the rest of the drugs, we observed no global overlap in drug-tissue associations between the preclinical and clinical settings. Concurring with Jaeger et al. [<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-8" hwp:rel-id="ref-24">24</xref>], our results call into question the translational potential of the <italic toggle="yes">in vitro</italic> results.</p><p hwp:id="p-37">We have come to recognize that cancer cell lines do not fully recapitulate the molecular features of patient tumors they originate from [<xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-2" hwp:rel-id="ref-11">11</xref>, <xref ref-type="bibr" rid="c56" hwp:id="xref-ref-56-1" hwp:rel-id="ref-56">56</xref>], which may hinder the translation of <bold><italic toggle="yes">in vitro</italic></bold> drug development to clinical settings [<xref ref-type="bibr" rid="c55" hwp:id="xref-ref-55-2" hwp:rel-id="ref-55">55</xref>, <xref ref-type="bibr" rid="c57" hwp:id="xref-ref-57-1" hwp:rel-id="ref-57">57</xref>–<xref ref-type="bibr" rid="c60" hwp:id="xref-ref-60-1" hwp:rel-id="ref-60">60</xref>]. It is hoped that large panels of cancer cell lines will enable faithful representation of the molecular diversity observed in patient tumours [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-5" hwp:rel-id="ref-18">18</xref>, <xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-2" hwp:rel-id="ref-19">19</xref>, <xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-5" hwp:rel-id="ref-23">23</xref>]. However, recent studies identified cell lines exhibiting molecular phenotypes that are not observed in patients [<xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-2" hwp:rel-id="ref-12">12</xref>, <xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-2" hwp:rel-id="ref-13">13</xref>], casting doubts on the relevance of these model systems for biological investigation and drug screening. Another fundamental problem in cancer cell line studies is the lack of a standard nomenclature to uniquely annotate cell lines to their tissue of origin [<xref ref-type="bibr" rid="c16" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref>, <xref ref-type="bibr" rid="c61" hwp:id="xref-ref-61-1" hwp:rel-id="ref-61">61</xref>, <xref ref-type="bibr" rid="c62" hwp:id="xref-ref-62-1" hwp:rel-id="ref-62">62</xref>], even though ontologies are under active development [<xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-2" hwp:rel-id="ref-35">35</xref>, <xref ref-type="bibr" rid="c63" hwp:id="xref-ref-63-1" hwp:rel-id="ref-63">63</xref>]. Lastly, cancer cell lines lack the tumor microenvironment, which has recently been shown to have a substantial effect on drug response and resistance [<xref ref-type="bibr" rid="c64" hwp:id="xref-ref-64-1" hwp:rel-id="ref-64">64</xref>, <xref ref-type="bibr" rid="c65" hwp:id="xref-ref-65-1" hwp:rel-id="ref-65">65</xref>]. Patient-derived organoids and xenografts are now new models of choice for drug screening and their usage might alleviate the current limitations of cancer cell lines [<xref ref-type="bibr" rid="c9" hwp:id="xref-ref-9-2" hwp:rel-id="ref-9">9</xref>, <xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-3" hwp:rel-id="ref-10">10</xref>, <xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-2" hwp:rel-id="ref-25">25</xref>]. These are key factors that are likely to contribute to the discrepancy between preclinical and clinical observations highlighted in this study. Although our meta-analysis provides the largest repository of <italic toggle="yes">in vitro</italic> drug-tissue associations to date, our results call for further investigations with the aim to improve the translational potential of cancer cell lines.</p></sec><sec id="s5" hwp:id="sec-12"><title hwp:id="title-20">CONCLUSION</title><p hwp:id="p-38">Our meta-analysis of pan-cancer <italic toggle="yes">in vitro</italic> drug screening datasets indicates that most approved and experimental drugs exhibit tissue-specific sensitivities in large panel of cancer cell lines. However, it is equally clear that the preclinical results do not translate to clinical setting, as the vast majority of <italic toggle="yes">in vitro</italic> drug-tissue associations are not recapitulated in clinical trials. Our results suggest that additional research is required to improve the translational potential of cancer cell lines for drug screening.</p></sec></body><back><ref-list hwp:id="ref-list-1"><title hwp:id="title-21">REFERENCES</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><label>1</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><collab hwp:id="collab-1">Cancer Genome Atlas Research Network</collab>. <article-title hwp:id="article-title-2">Comprehensive genomic characterization defines human glioblastoma genes and core pathways</article-title>. <source hwp:id="source-1">Nature</source> <year>2008</year>;<volume>455</volume>:<fpage>1061</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1"><label>2</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><collab hwp:id="collab-2">International Cancer Genome Consortium</collab>, <string-name name-style="western" hwp:sortable="Hudson TJ"><surname>Hudson</surname>, <given-names>TJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Anderson W"><surname>Anderson</surname>, <given-names>W</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-3">International network of cancer genome projects</article-title>. <source hwp:id="source-2">Nature</source> <year>2010</year>;<volume>464</volume>:<fpage>993</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1"><label>3</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Liu Z"><surname>Liu</surname>, <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhang S"><surname>Zhang</surname>, <given-names>S</given-names></string-name>. <article-title hwp:id="article-title-4">Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features</article-title>. <source hwp:id="source-3">BMC Genomics</source> <year>2015</year>;<volume>16</volume>:<fpage>503</fpage>.</citation></ref><ref id="c4" hwp:id="ref-4"><label>4</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Wang B"><surname>Wang</surname>, <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mezlini AM"><surname>Mezlini</surname>, <given-names>AM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Demir F"><surname>Demir</surname>, <given-names>F</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-5">Similarity network fusion for aggregating data types on a genomic scale</article-title>. <source hwp:id="source-4">Nat Methods</source> <year>2014</year>;<volume>11</volume>:<fpage>333</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1"><label>5</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Hoadley KA"><surname>Hoadley</surname>, <given-names>KA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yau C"><surname>Yau</surname>, <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wolf DM"><surname>Wolf</surname>, <given-names>DM</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-6">Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin</article-title>. <source hwp:id="source-5">Cell</source> <year>2014</year>;<volume>158</volume>:<fpage>929</fpage>–<lpage>44</lpage>.</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1 xref-ref-6-2"><label>6</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Cohen RL"><surname>Cohen</surname>, <given-names>RL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Settleman J"><surname>Settleman</surname>, <given-names>J</given-names></string-name>. <article-title hwp:id="article-title-7">From cancer genomics to precision oncology-tissue’s still an issue</article-title>. <source hwp:id="source-6">Cell</source> <year>2014</year>;<volume>157</volume>:<fpage>1509</fpage>–<lpage>14</lpage>.</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><label>7</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Barlas S"><surname>Barlas</surname>, <given-names>S</given-names></string-name>. <article-title hwp:id="article-title-8">The clinical trial model is up for review: time, expense, and quality of results are at issue, as is the relationship to drug pricing</article-title>. <source hwp:id="source-7">P T</source> <year>2014</year>;<volume>39</volume>:<fpage>691</fpage>–<lpage>4</lpage>.</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1"><label>8</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Macarron R"><surname>Macarron</surname>, <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Banks MN"><surname>Banks</surname>, <given-names>MN</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bojanic D"><surname>Bojanic</surname>, <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-9">Impact of high-throughput screening in biomedical research</article-title>. <source hwp:id="source-8">Nat Rev Drug Discov</source> <year>2011</year>;<volume>10</volume>:<fpage>188</fpage>–<lpage>95</lpage>.</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1 xref-ref-9-2"><label>9</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Gao H"><surname>Gao</surname>, <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Korn JM"><surname>Korn</surname>, <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ferretti S"><surname>Ferretti</surname>, <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-10">High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response</article-title>. <source hwp:id="source-9">Nat Med</source> <year>2015</year>;<volume>21</volume>:<fpage>1318</fpage>–<lpage>25</lpage>.</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1 xref-ref-10-2 xref-ref-10-3"><label>10</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Bruna A"><surname>Bruna</surname>, <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rueda OM"><surname>Rueda</surname>, <given-names>OM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Greenwood W"><surname>Greenwood</surname>, <given-names>W</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-11">A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds</article-title>. <source hwp:id="source-10">Cell</source> <year>2016</year>;<volume>167</volume>:<fpage>260</fpage>–<lpage>74.e22</lpage>.</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1 xref-ref-11-2"><label>11</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Gillet J-P"><surname>Gillet</surname>, <given-names>J-P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Varma S"><surname>Varma</surname>, <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gottesman MM"><surname>Gottesman</surname>, <given-names>MM</given-names></string-name>. <article-title hwp:id="article-title-12">The clinical relevance of cancer cell lines</article-title>. <source hwp:id="source-11">J Natl Cancer Inst</source> <year>2013</year>;<volume>105</volume>:<fpage>452</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1 xref-ref-12-2"><label>12</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Domcke S"><surname>Domcke</surname>, <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sinha R"><surname>Sinha</surname>, <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Levine DA"><surname>Levine</surname>, <given-names>DA</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-13">Evaluating cell lines as tumour models by comparison of genomic profiles</article-title>. <source hwp:id="source-12">Nat Commun</source> <year>2013</year>;<volume>4</volume>:<fpage>2126</fpage>.</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1 xref-ref-13-2"><label>13</label><citation publication-type="other" citation-type="journal" ref:id="085357v1.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Sinha R"><surname>Sinha</surname>, <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schultz N"><surname>Schultz</surname>, <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sander C"><surname>Sander</surname>, <given-names>C</given-names></string-name>. <article-title hwp:id="article-title-14">Comparing cancer cell lines and tumor samples by genomic profiles</article-title>. <source hwp:id="source-13">bioRxiv.</source> <year>2015</year>;:<fpage>028159</fpage>. doi:<pub-id pub-id-type="doi">10.1101/028159</pub-id></citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1"><label>14</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Hughes P"><surname>Hughes</surname>, <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Marshall D"><surname>Marshall</surname>, <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Reid Y"><surname>Reid</surname>, <given-names>Y</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-15">The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?</article-title> <source hwp:id="source-14">Biotechniques</source> <year>2007</year>;<volume>43</volume>:<fpage>575</fpage>, 577–8, 581–2 passim.</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1"><label>15</label><citation publication-type="other" citation-type="journal" ref:id="085357v1.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><article-title hwp:id="article-title-16">Identity crisis</article-title>. <source hwp:id="source-15">Nature</source> <year>2009</year>;<volume>457</volume>:<fpage>935</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1"><label>16</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Yu M"><surname>Yu</surname>, <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Selvaraj SK"><surname>Selvaraj</surname>, <given-names>SK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liang-Chu MMY"><surname>Liang-Chu</surname>, <given-names>MMY</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-17">A resource for cell line authentication, annotation and quality control</article-title>. <source hwp:id="source-16">Nature</source> <year>2015</year>;<volume>520</volume>:<fpage>307</fpage>–<lpage>11</lpage>.</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1"><label>17</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Masters JR"><surname>Masters</surname>, <given-names>JR</given-names></string-name>. <article-title hwp:id="article-title-18">False cell lines: The problem and a solution</article-title>. <source hwp:id="source-17">Cytotechnology</source> <year>2002</year>;<volume>39</volume>:<fpage>69</fpage>–<lpage>74</lpage>.</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1 xref-ref-18-2 xref-ref-18-3 xref-ref-18-4 xref-ref-18-5"><label>18</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Barretina J"><surname>Barretina</surname>, <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Caponigro G"><surname>Caponigro</surname>, <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stransky N"><surname>Stransky</surname>, <given-names>N</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-19">The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title>. <source hwp:id="source-18">Nature</source> <year>2012</year>;<volume>483</volume>:<fpage>603</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1 xref-ref-19-2"><label>19</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Garnett MJ"><surname>Garnett</surname>, <given-names>MJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Edelman EJ"><surname>Edelman</surname>, <given-names>EJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Heidorn SJ"><surname>Heidorn</surname>, <given-names>SJ</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-20">Systematic identification of genomic markers of drug sensitivity in cancer cells</article-title>. <source hwp:id="source-19">Nature</source> <year>2012</year>;<volume>483</volume>:<fpage>570</fpage>–<lpage>5</lpage>.</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1 xref-ref-20-2"><label>20</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Haverty PM"><surname>Haverty</surname>, <given-names>PM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lin E"><surname>Lin</surname>, <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tan J"><surname>Tan</surname>, <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-21">Reproducible pharmacogenomic profiling of cancer cell line panels</article-title>. <source hwp:id="source-20">Nature</source> <year>2016</year>;<volume>533</volume>:<fpage>333</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1 xref-ref-21-2 xref-ref-21-3"><label>21</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Seashore-Ludlow B"><surname>Seashore-Ludlow</surname>, <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rees MG"><surname>Rees</surname>, <given-names>MG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cheah JH"><surname>Cheah</surname>, <given-names>JH</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-22">Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset</article-title>. <source hwp:id="source-21">Cancer Discov</source> <year>2015</year>;<volume>5</volume>:<fpage>1210</fpage>–<lpage>23</lpage>.</citation></ref><ref id="c22" hwp:id="ref-22"><label>22</label><citation publication-type="book/journal" citation-type="journal" ref:id="085357v1.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Shoemaker RH"><surname>Shoemaker</surname>, <given-names>RH</given-names></string-name>. <article-title hwp:id="article-title-23">The NCI60 human tumour cell line anticancer drug screen</article-title>. <source hwp:id="source-22">Nat Rev Cancer</source> <year>2006</year>;<volume>6</volume>:<fpage>813</fpage>–<lpage>23</lpage>.</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1 xref-ref-23-2 xref-ref-23-3 xref-ref-23-4 xref-ref-23-5"><label>23</label><citation publication-type="other" citation-type="journal" ref:id="085357v1.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Iorio F"><surname>Iorio</surname>, <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Knijnenburg TA"><surname>Knijnenburg</surname>, <given-names>TA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vis DJ"><surname>Vis</surname>, <given-names>DJ</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-24">A Landscape of Pharmacogenomic Interactions in Cancer</article-title>. <source hwp:id="source-23">Cell</source> Published Online First: <day>5</day> <month>July</month> <year>2016</year>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2016.06.017</pub-id></citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1 xref-ref-24-2 xref-ref-24-3 xref-ref-24-4 xref-ref-24-5 xref-ref-24-6 xref-ref-24-7 xref-ref-24-8"><label>24</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.24" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Jaeger S"><surname>Jaeger</surname>, <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Duran-Frigola M"><surname>Duran-Frigola</surname>, <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Aloy P"><surname>Aloy</surname>, <given-names>P</given-names></string-name>. <article-title hwp:id="article-title-25">Drug sensitivity in cancer cell lines is not tissue-specific</article-title>. <source hwp:id="source-24">Mol Cancer</source> <year>2015</year>;<volume>14</volume>:<fpage>40</fpage>.</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1 xref-ref-25-2"><label>25</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="van de Wetering M"><surname>van de Wetering</surname>, <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Francies HE"><surname>Francies</surname>, <given-names>HE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Francis JM"><surname>Francis</surname>, <given-names>JM</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-26">Prospective derivation of a living organoid biobank of colorectal cancer patients</article-title>. <source hwp:id="source-25">Cell</source> <year>2015</year>;<volume>161</volume>:<fpage>933</fpage>–<lpage>45</lpage>.</citation></ref><ref id="c26" hwp:id="ref-26" hwp:rev-id="xref-ref-26-1"><label>26</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Wilding JL"><surname>Wilding</surname>, <given-names>JL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bodmer WF"><surname>Bodmer</surname>, <given-names>WF</given-names></string-name>. <article-title hwp:id="article-title-27">Cancer cell lines for drug discovery and development</article-title>. <source hwp:id="source-26">Cancer Res</source> <year>2014</year>;<volume>74</volume>:<fpage>2377</fpage>–<lpage>84</lpage>.</citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1 xref-ref-27-2"><label>27</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Haibe-Kains B"><surname>Haibe-Kains</surname>, <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="El-Hachem N"><surname>El-Hachem</surname>, <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Birkbak NJ"><surname>Birkbak</surname>, <given-names>NJ</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-28">Inconsistency in large pharmacogenomic studies</article-title>. <source hwp:id="source-27">Nature</source> <year>2013</year>;<volume>504</volume>:<fpage>389</fpage>–<lpage>93</lpage>.</citation></ref><ref id="c28" hwp:id="ref-28" hwp:rev-id="xref-ref-28-1"><label>28</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><collab hwp:id="collab-3">Cancer Cell Line Encyclopedia Consortium, Genomics of Drug Sensitivity in Cancer Consortium</collab>. <article-title hwp:id="article-title-29">Pharmacogenomic agreement between two cancer cell line data sets</article-title>. <source hwp:id="source-28">Nature</source> <year>2015</year>;<volume>528</volume>:<fpage>84</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c29" hwp:id="ref-29"><label>29</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Safikhani Z"><surname>Safikhani</surname>, <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="El-Hachem N"><surname>El-Hachem</surname>, <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Quevedo R"><surname>Quevedo</surname>, <given-names>R</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-30">Assessment of pharmacogenomic agreement</article-title>. <source hwp:id="source-29">F1000Res</source> <year>2016</year>;<volume>5</volume>:<fpage>825</fpage>.</citation></ref><ref id="c30" hwp:id="ref-30" hwp:rev-id="xref-ref-30-1 xref-ref-30-2"><label>30</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Safikhani Z"><surname>Safikhani</surname>, <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Smirnov P"><surname>Smirnov</surname>, <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Freeman M"><surname>Freeman</surname>, <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-31">Revisiting inconsistency in large pharmacogenomic studies</article-title>. <source hwp:id="source-30">F1000Res</source> <year>2016</year>;<volume>5</volume>:<fpage>2333</fpage>.</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1"><label>31</label><citation publication-type="other" citation-type="journal" ref:id="085357v1.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Hatzis C"><surname>Hatzis</surname>, <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bedard PL"><surname>Bedard</surname>, <given-names>PL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Juul Birkbak N"><surname>Juul Birkbak</surname>, <given-names>N</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-32">Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?</article-title> <source hwp:id="source-31">Cancer Res</source> Published Online First: <day>11</day> <month>July</month> <year>2014</year>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0725</pub-id></citation></ref><ref id="c32" hwp:id="ref-32" hwp:rev-id="xref-ref-32-1 xref-ref-32-2 xref-ref-32-3 xref-ref-32-4 xref-ref-32-5 xref-ref-32-6 xref-ref-32-7"><label>32</label><citation publication-type="other" citation-type="journal" ref:id="085357v1.32" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="Smirnov P"><surname>Smirnov</surname>, <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Safikhani Z"><surname>Safikhani</surname>, <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="El-Hachem N"><surname>El-Hachem</surname>, <given-names>N</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-33">PharmacoGx: An R package for analysis of large pharmacogenomic datasets</article-title>. <source hwp:id="source-32">Bioinformatics</source> Published Online First: <day>9</day> <month>December</month> <year>2015</year>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btv723</pub-id></citation></ref><ref id="c33" hwp:id="ref-33" hwp:rev-id="xref-ref-33-1"><label>33</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Yang W"><surname>Yang</surname>, <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Soares J"><surname>Soares</surname>, <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Greninger P"><surname>Greninger</surname>, <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-34">Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title>. <source hwp:id="source-33">Nucleic Acids Res</source> <year>2013</year>;<volume>41</volume>:<fpage>D955</fpage>–<lpage>61</lpage>.</citation></ref><ref id="c34" hwp:id="ref-34" hwp:rev-id="xref-ref-34-1"><label>34</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.34" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Basu A"><surname>Basu</surname>, <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bodycombe NE"><surname>Bodycombe</surname>, <given-names>NE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cheah JH"><surname>Cheah</surname>, <given-names>JH</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-35">An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules</article-title>. <source hwp:id="source-34">Cell</source> <year>2013</year>;<volume>154</volume>:<fpage>1151</fpage>–<lpage>61</lpage>.</citation></ref><ref id="c35" hwp:id="ref-35" hwp:rev-id="xref-ref-35-1 xref-ref-35-2"><label>35</label><citation publication-type="website" citation-type="web" ref:id="085357v1.35" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-35"><string-name name-style="western" hwp:sortable="Bairoch A"><surname>Bairoch</surname>, <given-names>A</given-names></string-name>. <source hwp:id="source-35">ExPASy - Cellosaurus</source>. Cellosaurus. 2015. <ext-link l:rel="related" l:ref-type="uri" l:ref="http://web.expasy.org/cellosaurus/" ext-link-type="uri" xlink:href="http://web.expasy.org/cellosaurus/" hwp:id="ext-link-4">http://web.expasy.org/cellosaurus/</ext-link> (accessed <day>26</day> <month>Jan</month> <year>2016</year>).</citation></ref><ref id="c36" hwp:id="ref-36" hwp:rev-id="xref-ref-36-1"><label>36</label><citation publication-type="other" citation-type="journal" ref:id="085357v1.36" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-36"><string-name name-style="western" hwp:sortable="Anderson E"><surname>Anderson</surname>, <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Veith GD"><surname>Veith</surname>, <given-names>GD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Weininger D"><surname>Weininger</surname>, <given-names>D</given-names></string-name>. <source hwp:id="source-36">SMILES, a Line Notation and Computerized Interpreter for Chemical Structures</source>. <year>1987</year>.</citation></ref><ref id="c37" hwp:id="ref-37" hwp:rev-id="xref-ref-37-1"><label>37</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.37" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-37"><string-name name-style="western" hwp:sortable="Wang Y"><surname>Wang</surname>, <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Xiao J"><surname>Xiao</surname>, <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Suzek TO"><surname>Suzek</surname>, <given-names>TO</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-36">PubChem: a public information system for analyzing bioactivities of small molecules</article-title>. <source hwp:id="source-37">Nucleic Acids Res</source> <year>2009</year>;<volume>37</volume>:<fpage>W623</fpage>–<lpage>33</lpage>.</citation></ref><ref id="c38" hwp:id="ref-38" hwp:rev-id="xref-ref-38-1"><label>38</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.38" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-38"><string-name name-style="western" hwp:sortable="Heller S"><surname>Heller</surname>, <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="McNaught A"><surname>McNaught</surname>, <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stein S"><surname>Stein</surname>, <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-37">InChI-the worldwide chemical structure identifier standard</article-title>. <source hwp:id="source-38">J Cheminform</source> <year>2013</year>;<volume>5</volume>:<fpage>1</fpage>.</citation></ref><ref id="c39" hwp:id="ref-39" hwp:rev-id="xref-ref-39-1"><label>39</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.39" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-39"><string-name name-style="western" hwp:sortable="Forbes SA"><surname>Forbes</surname>, <given-names>SA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Beare D"><surname>Beare</surname>, <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gunasekaran P"><surname>Gunasekaran</surname>, <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-38">COSMIC: exploring the world's knowledge of somatic mutations in human cancer</article-title>. <source hwp:id="source-39">Nucleic Acids Res</source> <year>2015</year>;<volume>43</volume>:<fpage>D805</fpage>–<lpage>11</lpage>.</citation></ref><ref id="c40" hwp:id="ref-40" hwp:rev-id="xref-ref-40-1"><label>40</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.40" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-40"><string-name name-style="western" hwp:sortable="Fallahi-Sichani M"><surname>Fallahi-Sichani</surname>, <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Honarnejad S"><surname>Honarnejad</surname>, <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Heiser LM"><surname>Heiser</surname>, <given-names>LM</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-39">Metrics other than potency reveal systematic variation in responses to cancer drugs</article-title>. <source hwp:id="source-40">Nat Chem Biol</source> <year>2013</year>;<volume>9</volume>:<fpage>708</fpage>–<lpage>14</lpage>.</citation></ref><ref id="c41" hwp:id="ref-41" hwp:rev-id="xref-ref-41-1"><label>41</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.41" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-41"><string-name name-style="western" hwp:sortable="Subramanian A"><surname>Subramanian</surname>, <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tamayo P"><surname>Tamayo</surname>, <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mootha VK"><surname>Mootha</surname>, <given-names>VK</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-40">Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source hwp:id="source-41">Proc Natl Acad Sci U S A</source> <year>2005</year>;<volume>102</volume>:<fpage>15545</fpage>–<lpage>50</lpage>.</citation></ref><ref id="c42" hwp:id="ref-42" hwp:rev-id="xref-ref-42-1"><label>42</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.42" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-42"><string-name name-style="western" hwp:sortable="Väremo L"><surname>Väremo</surname>, <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nielsen J"><surname>Nielsen</surname>, <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nookaew I"><surname>Nookaew</surname>, <given-names>I</given-names></string-name>. <article-title hwp:id="article-title-41">Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods</article-title>. <source hwp:id="source-42">Nucleic Acids Res</source> <year>2013</year>;<volume>41</volume>:<fpage>4378</fpage>–<lpage>91</lpage>.</citation></ref><ref id="c43" hwp:id="ref-43" hwp:rev-id="xref-ref-43-1"><label>43</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.43" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-43"><string-name name-style="western" hwp:sortable="Whitlock MC"><surname>Whitlock</surname>, <given-names>MC</given-names></string-name>. <article-title hwp:id="article-title-42">Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach</article-title>. <source hwp:id="source-43">J Evol Biol</source> <year>2005</year>;<volume>18</volume>:<fpage>1368</fpage>–<lpage>73</lpage>.</citation></ref><ref id="c44" hwp:id="ref-44" hwp:rev-id="xref-ref-44-1"><label>44</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.44" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-44"><string-name name-style="western" hwp:sortable="Schroder MS"><surname>Schroder</surname>, <given-names>MS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Culhane AC"><surname>Culhane</surname>, <given-names>AC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Quackenbush J"><surname>Quackenbush</surname>, <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-43">survcomp: an R/Bioconductor package for performance assessment and comparison of survival models</article-title>. <source hwp:id="source-44">Bioinformatics</source> <year>2011</year>;<volume>27</volume>:<fpage>3206</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c45" hwp:id="ref-45" hwp:rev-id="xref-ref-45-1"><label>45</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.45" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-45"><string-name name-style="western" hwp:sortable="Benjamini Y"><surname>Benjamini</surname>, <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hochberg Y"><surname>Hochberg</surname>, <given-names>Y</given-names></string-name>. <article-title hwp:id="article-title-44">Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing</article-title>. <source hwp:id="source-45">J R Stat Soc Series B Stat Methodol</source> <year>1995</year>;<volume>57</volume>:<fpage>289</fpage>–<lpage>300</lpage>.</citation></ref><ref id="c46" hwp:id="ref-46" hwp:rev-id="xref-ref-46-1"><label>46</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.46" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-46"><string-name name-style="western" hwp:sortable="Shannon P"><surname>Shannon</surname>, <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Markiel A"><surname>Markiel</surname>, <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ozier O"><surname>Ozier</surname>, <given-names>O</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-45">Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>. <source hwp:id="source-46">Genome Res</source> <year>2003</year>;<volume>13</volume>:<fpage>2498</fpage>–<lpage>504</lpage>.</citation></ref><ref id="c47" hwp:id="ref-47" hwp:rev-id="xref-ref-47-1"><label>47</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.47" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-47"><string-name name-style="western" hwp:sortable="Krzywinski M"><surname>Krzywinski</surname>, <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schein J"><surname>Schein</surname>, <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Birol I"><surname>Birol</surname>, <given-names>I</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-46">Circos: an information aesthetic for comparative genomics</article-title>. <source hwp:id="source-47">Genome Res</source> <year>2009</year>;<volume>19</volume>:<fpage>1639</fpage>–<lpage>45</lpage>.</citation></ref><ref id="c48" hwp:id="ref-48" hwp:rev-id="xref-ref-48-1"><label>48</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.48" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-48"><string-name name-style="western" hwp:sortable="Matthews BW"><surname>Matthews</surname>, <given-names>BW</given-names></string-name>. <article-title hwp:id="article-title-47">Comparison of the predicted and observed secondary structure of T4 phage lysozyme</article-title>. <source hwp:id="source-48">Biochim Biophys Acta</source> <year>1975</year>;<volume>405</volume>:<fpage>442</fpage>–<lpage>51</lpage>.</citation></ref><ref id="c49" hwp:id="ref-49" hwp:rev-id="xref-ref-49-1"><label>49</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.49" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-49"><string-name name-style="western" hwp:sortable="Sandve GK"><surname>Sandve</surname>, <given-names>GK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nekrutenko A"><surname>Nekrutenko</surname>, <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Taylor J"><surname>Taylor</surname>, <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-48">Ten simple rules for reproducible computational research</article-title>. <source hwp:id="source-49">PLoS Comput Biol</source> <year>2013</year>;<volume>9</volume>:<fpage>e1003285</fpage>.</citation></ref><ref id="c50" hwp:id="ref-50" hwp:rev-id="xref-ref-50-1"><label>50</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.50" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-50"><string-name name-style="western" hwp:sortable="Belmann P"><surname>Belmann</surname>, <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Droge J"><surname>Droge</surname>, <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bremges A"><surname>Bremges</surname>, <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-49">Bioboxes: standardised containers for interchangeable bioinformatics software</article-title>. <source hwp:id="source-50">Gigascience</source> <year>2015</year>;<volume>4</volume>:<fpage>47</fpage>.</citation></ref><ref id="c51" hwp:id="ref-51" hwp:rev-id="xref-ref-51-1 xref-ref-51-2 xref-ref-51-3 xref-ref-51-4"><label>51</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.51" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-51"><string-name name-style="western" hwp:sortable="Klijn C"><surname>Klijn</surname>, <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Durinck S"><surname>Durinck</surname>, <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stawiski EW"><surname>Stawiski</surname>, <given-names>EW</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-50">A comprehensive transcriptional portrait of human cancer cell lines</article-title>. <source hwp:id="source-51">Nat Biotechnol</source> <year>2015</year>;<volume>33</volume>:<fpage>306</fpage>–<lpage>12</lpage>.</citation></ref><ref id="c52" hwp:id="ref-52" hwp:rev-id="xref-ref-52-1 xref-ref-52-2 xref-ref-52-3 xref-ref-52-4"><label>52</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.52" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-52"><string-name name-style="western" hwp:sortable="Gupta S"><surname>Gupta</surname>, <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chaudhary K"><surname>Chaudhary</surname>, <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kumar R"><surname>Kumar</surname>, <given-names>R</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-51">Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine</article-title>. <source hwp:id="source-52">Sci Rep</source> <year>2016</year>;<volume>6</volume>:<fpage>23857</fpage>.</citation></ref><ref id="c53" hwp:id="ref-53" hwp:rev-id="xref-ref-53-1 xref-ref-53-2"><label>53</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.53" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-53"><string-name name-style="western" hwp:sortable="Garnett MJ"><surname>Garnett</surname>, <given-names>MJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="McDermott U"><surname>McDermott</surname>, <given-names>U</given-names></string-name>. <article-title hwp:id="article-title-52">The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response</article-title>. <source hwp:id="source-53">Curr Opin Genet Dev</source> <year>2014</year>;<volume>24</volume>:<fpage>114</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c54" hwp:id="ref-54" hwp:rev-id="xref-ref-54-1"><label>54</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.54" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-54"><string-name name-style="western" hwp:sortable="Chen B-J"><surname>Chen</surname>, <given-names>B-J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Litvin O"><surname>Litvin</surname>, <given-names>O</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ungar L"><surname>Ungar</surname>, <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-53">Context Sensitive Modeling of Cancer Drug Sensitivity</article-title>. <source hwp:id="source-54">PLoS One</source> <year>2015</year>;<volume>10</volume>:<fpage>e0133850</fpage>.</citation></ref><ref id="c55" hwp:id="ref-55" hwp:rev-id="xref-ref-55-1 xref-ref-55-2"><label>55</label><citation publication-type="other" citation-type="journal" ref:id="085357v1.55" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-55"><string-name name-style="western" hwp:sortable="Goodspeed A"><surname>Goodspeed</surname>, <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Heiser LM"><surname>Heiser</surname>, <given-names>LM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gray JW"><surname>Gray</surname>, <given-names>JW</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-54">Tumor-derived Cell Lines as Molecular Models of Cancer Pharmacogenomics</article-title>. <source hwp:id="source-55">Mol Cancer Res</source> Published Online First: <day>6</day> <month>August</month> <year>2015</year>. doi:<pub-id pub-id-type="doi">10.1158/1541-7786.MCR-15-0189</pub-id></citation></ref><ref id="c56" hwp:id="ref-56" hwp:rev-id="xref-ref-56-1"><label>56</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.56" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-56"><string-name name-style="western" hwp:sortable="Welsh M"><surname>Welsh</surname>, <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mangravite L"><surname>Mangravite</surname>, <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Medina MW"><surname>Medina</surname>, <given-names>MW</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-55">Pharmacogenomic discovery using cell-based models</article-title>. <source hwp:id="source-56">Pharmacol Rev</source> <year>2009</year>;<volume>61</volume>:<fpage>413</fpage>–<lpage>29</lpage>.</citation></ref><ref id="c57" hwp:id="ref-57" hwp:rev-id="xref-ref-57-1"><label>57</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.57" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-57"><string-name name-style="western" hwp:sortable="Gillet J-P"><surname>Gillet</surname>, <given-names>J-P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Calcagno AM"><surname>Calcagno</surname>, <given-names>AM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Varma S"><surname>Varma</surname>, <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-56">Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance</article-title>. <source hwp:id="source-57">Proc Natl Acad Sci U S A</source> <year>2011</year>;<volume>108</volume>:<fpage>18708</fpage>–<lpage>13</lpage>.</citation></ref><ref id="c58" hwp:id="ref-58"><label>58</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.58" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-58"><string-name name-style="western" hwp:sortable="McDermott M"><surname>McDermott</surname>, <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Eustace AJ"><surname>Eustace</surname>, <given-names>AJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Busschots S"><surname>Busschots</surname>, <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-57">In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies</article-title>. <source hwp:id="source-58">Front Oncol</source> <year>2014</year>;<volume>4</volume>:<fpage>40</fpage>.</citation></ref><ref id="c59" hwp:id="ref-59"><label>59</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.59" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-59"><string-name name-style="western" hwp:sortable="Kamb A"><surname>Kamb</surname>, <given-names>A</given-names></string-name>. <article-title hwp:id="article-title-58">What's wrong with our cancer models?</article-title> <source hwp:id="source-59">Nat Rev Drug Discov</source> <year>2005</year>;<volume>4</volume>:<fpage>161</fpage>–<lpage>5</lpage>.</citation></ref><ref id="c60" hwp:id="ref-60" hwp:rev-id="xref-ref-60-1"><label>60</label><citation publication-type="other" citation-type="journal" ref:id="085357v1.60" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-60"><string-name name-style="western" hwp:sortable="Horvath P"><surname>Horvath</surname>, <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Aulner N"><surname>Aulner</surname>, <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bickle M"><surname>Bickle</surname>, <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-59">Screening out irrelevant cell-based models of disease</article-title>. <source hwp:id="source-60">Nat Rev Drug Discov</source> Published Online First: <day>12</day> <month>September</month> <year>2016</year>. doi:<pub-id pub-id-type="doi">10.1038/nrd.2016.175</pub-id></citation></ref><ref id="c61" hwp:id="ref-61" hwp:rev-id="xref-ref-61-1"><label>61</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.61" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-61"><string-name name-style="western" hwp:sortable="Almeida JL"><surname>Almeida</surname>, <given-names>JL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cole KD"><surname>Cole</surname>, <given-names>KD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Plant AL"><surname>Plant</surname>, <given-names>AL</given-names></string-name>. <article-title hwp:id="article-title-60">Standards for Cell Line Authentication and Beyond</article-title>. <source hwp:id="source-61">PLoS Biol</source> <year>2016</year>;<volume>14</volume>:<fpage>e1002476</fpage>.</citation></ref><ref id="c62" hwp:id="ref-62" hwp:rev-id="xref-ref-62-1"><label>62</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.62" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-62"><string-name name-style="western" hwp:sortable="Freedman LP"><surname>Freedman</surname>, <given-names>LP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gibson MC"><surname>Gibson</surname>, <given-names>MC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ethier SP"><surname>Ethier</surname>, <given-names>SP</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-61">Reproducibility: changing the policies and culture of cell line authentication</article-title>. <source hwp:id="source-62">Nat Methods</source> <year>2015</year>;<volume>12</volume>:<fpage>493</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c63" hwp:id="ref-63" hwp:rev-id="xref-ref-63-1"><label>63</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.63" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-63"><string-name name-style="western" hwp:sortable="Sarntivijai S"><surname>Sarntivijai</surname>, <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lin Y"><surname>Lin</surname>, <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Xiang Z"><surname>Xiang</surname>, <given-names>Z</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-62">CLO: The cell line ontology</article-title>. <source hwp:id="source-63">J Biomed Semantics</source> <year>2014</year>;<volume>5</volume>:<fpage>37</fpage>.</citation></ref><ref id="c64" hwp:id="ref-64" hwp:rev-id="xref-ref-64-1"><label>64</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.64" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-64"><string-name name-style="western" hwp:sortable="Mumenthaler SM"><surname>Mumenthaler</surname>, <given-names>SM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Foo J"><surname>Foo</surname>, <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Choi NC"><surname>Choi</surname>, <given-names>NC</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-63">The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells</article-title>. <source hwp:id="source-64">Cancer Inform</source> <year>2015</year>;<volume>14</volume>:<fpage>19</fpage>–<lpage>31</lpage>.</citation></ref><ref id="c65" hwp:id="ref-65" hwp:rev-id="xref-ref-65-1"><label>65</label><citation publication-type="journal" citation-type="journal" ref:id="085357v1.65" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-65"><string-name name-style="western" hwp:sortable="Trédan O"><surname>Trédan</surname>, <given-names>O</given-names></string-name>, <string-name name-style="western" hwp:sortable="Galmarini CM"><surname>Galmarini</surname>, <given-names>CM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Patel K"><surname>Patel</surname>, <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-64">Drug resistance and the solid tumor microenvironment</article-title>. <source hwp:id="source-65">J Natl Cancer Inst</source> <year>2007</year>;<volume>99</volume>:<fpage>1441</fpage>–<lpage>54</lpage>.</citation></ref></ref-list><ack hwp:id="ack-1"><title hwp:id="title-22">ACKNOWLEDGEMENTS</title><p hwp:id="p-39">The authors would like to thank Drs. Samira Jaeger and Patrick Aloy for their constructive and insightful feedback on our study.</p></ack><sec id="s6" hwp:id="sec-13"><title hwp:id="title-23">AUTHOR CONTRIBUTIONS</title><p hwp:id="p-40">F.Y, Z.S and S.A.A.T contributed equally to this work. F.Y, Z.S and S.A.A.T wrote the code, performed the analysis and interpreted the results. Z.S, P.S and M.F collected and fitted the drug dose-response curves. N.E-H curated the cell lines and drug annotations. F.Y and V.S.K.M performed the tissue enrichment analysis. B.H.K supervised the study. F.Y, S.A.A.T, V.S.K.M wrote the first version of the manuscript.</p></sec><sec id="s7" hwp:id="sec-14"><title hwp:id="title-24">FUNDING</title><p hwp:id="p-41">This study was conducted with the support of the Canadian Cancer Research Society and the Ontario Institute for Cancer Research through funding provided by the Government of Ontario. S.A.A.T was supported by a Connaught International Scholarship. Z.S was supported by the Cancer Research Society (Canada). N.E-H was supported by the Ministry of Economic Development, Employment and Infrastructure and the Ministry of Innovation of the Government of Ontario. B.H.K was supported by the Gattuso-Slaight Personalized Cancer Medicine Fund at Princess Margaret Cancer Centre and the Canadian Institutes of Health Research.</p></sec><sec id="s8" sec-type="COI-statement" hwp:id="sec-15"><title hwp:id="title-25">COMPETING FINANCIAL INTERESTS</title><p hwp:id="p-42">The authors declare no competing financial interests.</p></sec><sec id="s9" sec-type="supplementary-material" hwp:id="sec-16"><title hwp:id="title-26">SUPPLEMENTARY FIGURES</title><fig id="figS1" position="float" orientation="portrait" fig-type="figure" hwp:id="F8"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/FIGS1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F8</object-id><object-id pub-id-type="publisher-id">figS1</object-id><label>Supplementary Figure 1:</label><caption hwp:id="caption-10"><title hwp:id="title-27">Schematic describing our tissue enrichment analysis (TEA).</title><p hwp:id="p-43">Our method is adapted from the gene set enrichment analysis (GSEA) where gene sets are replaced by sets of cell lines representing each tissue type. Breast is an example of strong drug-tissue association, as the breast cancer cell lines are all highly sensitivity (high AUC). On the contrary, the pleura tissue is not enriched in sensitive cell lines.</p></caption><graphic xlink:href="085357_figS1" position="float" orientation="portrait" hwp:id="graphic-10"/></fig><fig id="figS2" position="float" orientation="portrait" fig-type="figure" hwp:id="F9"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;085357v1/FIGS2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F9</object-id><object-id pub-id-type="publisher-id">figS2</object-id><label>Supplementary Figure 2:</label><caption hwp:id="caption-11"><title hwp:id="title-28">Heatmap showing the significance of the drug-tissue associations (FDR) for the drugs and tissue types in common between NCI60 and our compendium of datasets.</title><p hwp:id="p-44">(<bold>A</bold>) Tissue enrichment analysis (TEA) performed using the NCI60 data only. (<bold>B</bold>) TEA using our compendium of pharmacogenomic datasets. FDR &lt; 0.001 in green; 0.001 ≤ FDR &lt; 0.01 in orange; 0.01 ≤ FDR &lt; 0.05 in blue; and FDR ≥ 0.05 in grey. Drug-tissue associations that were not tested due to lack of drug sensitivity data are represented white.</p></caption><graphic xlink:href="085357_figS2" position="float" orientation="portrait" hwp:id="graphic-11"/></fig><p hwp:id="p-45"><bold>Supplementary Figure 3: Heatmap showing the significance of the drug-tissue associations (FDR) for all the drugs and tissue types in the NCI60 dataset.</bold> Only the drug with at least one association as determined by the tissue enrichment analysis (TEA) are represented. FDR &lt; 0.001 in green; 0.001 ≤ FDR &lt; 0.01 in orange; 0.01 ≤ FDR &lt; 0.05 in blue; and FDR ≥ 0.05 in grey. Drug-tissue associations that were not tested due to lack of drug sensitivity data are represented white.</p></sec><sec id="s10" sec-type="supplementary-material" hwp:id="sec-17"><title hwp:id="title-29">SUPPLEMENTARY FILES</title><p hwp:id="p-46"><bold>Supplementary File 1: List of drugs in our compendium of pharmacogenomic datasets (CCLE, GDSC1000, CTRPv2, gCSI) and NCI60.</bold></p><p hwp:id="p-47"><bold>Supplementary File 2: Dataset-specific enrichment scores, associated p-values, and the false discovery rates for the drugs screened in at least 3 datasets.</bold> Each sheet reports the results for a drug.</p><p hwp:id="p-48"><bold>Supplementary File 3: False discovery rates for all the the drug-tissue associations tested in our compendium of large pharmacogenomic datasets.</bold> False discovery rates are computed from the combined p-values obtained from the tissue enrichment analysis performed in each dataset separately.</p><p hwp:id="p-49"><bold>Supplementary File 4: False discovery rates for all the the drug-tissue associations tested in the NCI60 dataset.</bold> False discovery rates are computed from the p-values obtained from the tissue enrichment analysis.</p></sec><sec id="s11" sec-type="supplementary-material" hwp:id="sec-18"><title hwp:id="title-30">Supplementary Methods</title><sec id="s11a" hwp:id="sec-19"><title hwp:id="title-31">Full Reproducibility of the Analysis Results</title><p hwp:id="p-50">We describe below how to fully reproduce the figures and tables reported in the paper
<list list-type="order" hwp:id="list-1"><list-item hwp:id="list-item-1"><p hwp:id="p-51">Set up the software environment</p></list-item><list-item hwp:id="list-item-2"><p hwp:id="p-52">Run the R scripts</p></list-item><list-item hwp:id="list-item-3"><p hwp:id="p-53">Generate figures</p></list-item></list></p></sec><sec id="s11b" hwp:id="sec-20"><title hwp:id="title-32">Set up the software environment</title><p hwp:id="p-54">We developed and tested our analysis pipeline using R running on linux and Mac OSX platforms. The code is freely available from GitHub <monospace><ext-link l:rel="related" l:ref-type="uri" l:ref="https://github.com/bhklab/DrugTissue" ext-link-type="uri" xlink:href="https://github.com/bhklab/DrugTissue" hwp:id="ext-link-5">https://github.com/bhklab/DrugTissue</ext-link></monospace>. The following is a copy of <monospace>sessionInfo()</monospace> from the development environment in R
<preformat preformat-type="dialog" position="float" orientation="portrait" xml:space="preserve" hwp:id="preformat-1">
R version 3.3.0 (2016-05-03)
Platform: x86_64-redhat-linux-gnu (64-bit)
Running under: CentOS Linux 7 (Core)
</preformat>
<preformat preformat-type="dialog" position="float" orientation="portrait" xml:space="preserve" hwp:id="preformat-2">
attached base packages:
[1] grid     stats    graphics    grDevices utils   datasets
[7] methods  base
</preformat>
<preformat preformat-type="dialog" position="float" orientation="portrait" xml:space="preserve" hwp:id="preformat-3">
other attached packages:
 [1] pvclust_2.0-0        vegan_2.4-0       lattice_0.20-33
 [4] permute_0.9-0        survcomp_1.22.0   prodlim_1.5.7
 [7] survival_2.39-4      piano_1.12.0      xlsx_0.5.7
[10] xlsxjars_0.6.1       rJava_0.9-8       RColorBrewer_1.1-2
[13] gplots_3.0.1         mgcv_1.8-12       nlme_3.1-128
[16] ggplot2_2.1.0        reshape2_1.4.1    VennDiagram_1.6.17
[19] futile.logger_1.4.1  PharmacoGx_1.1.6
</preformat>
<preformat preformat-type="dialog" position="float" orientation="portrait" xml:space="preserve" hwp:id="preformat-4">
loaded via a namespace (and not attached):
 [1] gtools_3.5.0       lsa_0.73.1           slam_0.1-35
 [4] sets_1.0-16        splines_3.3.0        colorspace_1.2-6
 [7] SnowballC_0.5.1    marray_1.50.0        sm_2.2-5.4
[10] magicaxis_1.9.4    BiocGenerics_0.18.0  lambda.r_1.1.7
[13] plyr_1.8.4         lava_1.4.3           stringr_1.0.0
[16] munsell_0.4.3      survivalROC_1.0.3    gtable_0.2.0
[19] caTools_1.17.1     labeling_0.3         Biobase_2.32.0
[22] parallel_3.3.0     Rcpp_0.12.5          KernSmooth_2.23-15
[25] relations_0.6-6    scales_0.4.0         limma_3.28.11
[28] gdata_2.17.0       rmeta_2.16           plotrix_3.6-2
[31] bootstrap_2015.2   digest_0.6.9         stringi_1.1.1
[34] SuppDists_1.1-9.2  tools_3.3.0          bitops_1.0-6
[37] magrittr_1.5       cluster_2.0.4        futile.options_1.0.0
[40] MASS_7.3-45        Matrix_1.2-6         downloader_0.4
[43] igraph_1.0.1
</preformat>
</p><p hwp:id="p-55">All these packages are available on CRANor Bioconductor All necessary packages have <monospace>library(&lt;package&gt;)</monospace> calls within the R scripts themselves, or the script assumes a previous script has been run and thus should have loaded necessary packages.</p></sec><sec id="s11c" hwp:id="sec-21"><title hwp:id="title-33">Running R Scripts in Repository and Figure Generation</title><p hwp:id="p-56">It is mandatory for all scripts to be run within one RStudio instance, as scripts will reference generated output variables from other script files
<list list-type="order" hwp:id="list-2"><list-item hwp:id="list-item-4"><p hwp:id="p-57">Load CTRPv2, CCLE, GDSC1000, and gCSI using the <monospace>downloadPSet()</monospace> functions in PharmacoGx</p></list-item><list-item hwp:id="list-item-5"><p hwp:id="p-58">Run <monospace>GSEA_with_AUC.R</monospace> to get enrichment scores in one matrix variable called <monospace>combined1</monospace></p></list-item><list-item hwp:id="list-item-6"><p hwp:id="p-59">Load the XML clinicaltrials.gov reader from <monospace>drugResultGetter.R</monospace>, and run <monospace>wordmine.R</monospace> to generate the <monospace>wordmine</monospace> variable referenced in diagram generation</p></list-item><list-item hwp:id="list-item-7"><p hwp:id="p-60">All figures should run independently with varying pdf generation in working directory set using <monospace>setWD()</monospace></p></list-item><list-item hwp:id="list-item-8"><p hwp:id="p-61">All figures can be generated with their respectively R file</p></list-item><list-item hwp:id="list-item-9"><p hwp:id="p-62">The circos plot has been generated using Cytoscape for network visualization</p></list-item><list-item hwp:id="list-item-10"><p hwp:id="p-63">Supplementary File 3 is generated at the end of <monospace>GSEA_with_AUC.R</monospace></p></list-item><list-item hwp:id="list-item-11"><p hwp:id="p-64">In <monospace>GSEA_with_AUC.R</monospace>, a boolean variable paper is present to recreate the TEA analysis without hematopoietic and lymphoid tissue mentioned in the paper</p></list-item></list>
</p></sec></sec><sec id="s12" hwp:id="sec-22"><label>1</label><title hwp:id="title-34">Acronyms</title><def-list hwp:id="def-list-1"><def-item hwp:id="def-item-1"><term hwp:id="term-1">AUC</term><def hwp:id="def-1"><p hwp:id="p-65">Area under the drug dose-response curve</p></def></def-item><def-item hwp:id="def-item-2"><term hwp:id="term-2">CCLE</term><def hwp:id="def-2"><p hwp:id="p-66">The Cancer Cell Line Encyclopedia initiated by the Broad Institute of MIT and Harvard</p></def></def-item><def-item hwp:id="def-item-3"><term hwp:id="term-3">CGHub</term><def hwp:id="def-3"><p hwp:id="p-67">The Cancer Genomics Hub from the University of California Santa Cruz and the US National Cancer Institute</p></def></def-item><def-item hwp:id="def-item-4"><term hwp:id="term-4">COSMIC</term><def hwp:id="def-4"><p hwp:id="p-68">Catalogue of Somatic Mutations in Cancer by the Wellcome Trust Sanger Institute</p></def></def-item><def-item hwp:id="def-item-5"><term hwp:id="term-5">CTRPv2</term><def hwp:id="def-5"><p hwp:id="p-69">The Cancer Therapeutics Portal version 2 initiated by the Broad Institute of MIT and Harvard</p></def></def-item><def-item hwp:id="def-item-6"><term hwp:id="term-6">gCSI</term><def hwp:id="def-6"><p hwp:id="p-70">The Genentech Cell Line Screening Initiative</p></def></def-item><def-item hwp:id="def-item-7"><term hwp:id="term-7">GDSC1000</term><def hwp:id="def-7"><p hwp:id="p-71">The Genomics of Drug Sensitivity in Cancer led by the Wellcome Trust Sanger Institute</p></def></def-item><def-item hwp:id="def-item-8"><term hwp:id="term-8">MCC</term><def hwp:id="def-8"><p hwp:id="p-72">Matthew Correlation Coefficient</p></def></def-item></def-list></sec></back></article>
